セッション情報

FACO Poster Session

第56回・2018年・横浜
FACO Poster Session
FACO Poster Session 2
FACO Poster Session 2
開催回
第56回・2018年・横浜

How effective are psychological interventions for children with cancer and their parents? A multilevel meta-analysis and qualitative comparative analysis

演題番号 : FP2-1

Speaker)Therdpong Thongseiratch:1

1:Child Development Unit, Department of Pediatrics, Prince of Songkla University, Thailand

How effective are psychological interventions for children with cancer and their parents? A multilevel meta-analysis and qualitative comparative analysis

Role of glycogenolysis in acquired temozolomide resistance through [Ca2+]i-dependent activation of Na,K-ATPase/ERK1/2 signaling in glioma

演題番号 : FP2-2

Speaker)Junnan Xu:1、Ye Zhang:2、Tao Sun:1

1:Department of Medical Onocolgy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China、2:Department of Neurosurgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China

Role of glycogenolysis in acquired temozolomide resistance through [Ca2+]i-dependent activation of Na,K-ATPase/ERK1/2 signaling in glioma

演題取り下げ

演題番号 : FP2-3

演題取り下げ

演題取り下げ

演題番号 : FP2-4

演題取り下げ

Cost-effective analysis of concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma

演題番号 : FP2-5

Speaker)Weiting Liao:1,2、Jiaxing Huang:1,2、Qiu Li:1,2

1:Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China、2:West China Biomedical Big Data Center, Sichuan University, China

Cost-effective analysis of concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma

演題取り下げ

演題番号 : FP2-6

演題取り下げ

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or HER2-positive breast cancer

演題番号 : FP2-7

Speaker)Junnan Xu:1、Tao Sun:1

1:Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or HER2-positive breast cancer

The molecular features differences between the better prognosis and the poorer prognosis triple-negative breast cancers

演題番号 : FP2-8

Speaker)Junnan Xu:1、Tao Sun:1

1:Department of Medical Oncology, Cancer Hospital of China Medical University, China

The molecular features differences between the better prognosis and the poorer prognosis triple-negative breast cancers

Predictive value of CD4+/CD8+ ratio in patients with breast cancer receiving recombinant human thrombopoietin

演題番号 : FP2-9

Speaker)Junnan Xu:1,2、Tao Sun:1,2

1:Department of Medical University, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China、2:Key Laboratory of Liaoning Breast Cancer Research, China

Predictive value of CD4+/CD8+ ratio in patients with breast cancer receiving recombinant human thrombopoietin

Improvement of neurotoxicity outcome with Monosialotetrahexosylganglioside versus Trivitamin B in BC patients with Utidelone-induced Peripheral Neuropathy

演題番号 : FP2-10

Speaker)Junnan Xu:1、Tao Sun:1

1:Department of Medical Oncology, Cancer Hospital of China Medical University, China

Improvement of neurotoxicity outcome with Monosialotetrahexosylganglioside versus Trivitamin B in BC patients with Utidelone-induced Peripheral Neuropathy

Lymph node status guides taxane-based escalating and de-escalating chemotherapy in patients with early triple negative breast cancer

演題番号 : FP2-11

Speaker)Sanxing Guo:1、Suzhi Zhang:2、Na Wang:3、Yujie He:4、Xingya Li:1

1:Oncology Department, The First Affiliated Hospital of Zhengzhou University, China、2:Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, China、3:Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, China、4:Rheumatology and Immunology Department, The First Affiliated Hospital of Zhengzhou University, China

Lymph node status guides taxane-based escalating and de-escalating chemotherapy in patients with early triple negative breast cancer

The combination of NVP-BEZ235 and endostatin exerts synergistic anticancer activity against triple-negative breast cancer in vitro and in vivo

演題番号 : FP2-12

Speaker)Xiaoshan Wang:1、Xiao Zhang:2、Fanghua Li:3

1:Cancer Center, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China、2:Department of Breast Surgery, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China、3:Department of Pathology, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China

The combination of NVP-BEZ235 and endostatin exerts synergistic anticancer activity against triple-negative breast cancer in vitro and in vivo

Fulvestrant 500mg versus Exemestane in postmenopausal Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors (NSAI) in clinical practice

演題番号 : FP2-13

Speaker)Yizhao Xie:1、Biyun Wang:1、Yannan Zhao:1、Chengcheng Gong:1、Yi Li:1、Xichun Hu:1、Jian Zhang:1、Leiping Wang:1

1:Medical Oncology, Fudan University Shanghai Cancer Center, China

Fulvestrant 500mg versus Exemestane in postmenopausal Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors (NSAI) in clinical practice

Cost-effectiveness analysis of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine for HER2-negative metastatic breast cancer

演題番号 : FP2-14

Speaker)Qiuji Wu:1、Qiu Li:1

1:Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China

Cost-effectiveness analysis of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine for HER2-negative metastatic breast cancer

Concordance assessment of IBM Watson for oncology with MDT in patients with breast cancer

演題番号 : FP2-15

Speaker)Junnan Xu:1,2、Tao Sun:1,2

1:Department of Medical Onocolgy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China、2:Key Laboratory of Liaoning Breast Cancer Research, China

Concordance assessment of IBM Watson for oncology with MDT in patients with breast cancer

演題取り下げ

演題番号 : FP2-16

演題取り下げ

演題取り下げ

演題番号 : FP2-17

演題取り下げ

演題取り下げ

演題番号 : FP2-18

演題取り下げ

Postoperative micropapillary lung adenocarcinoma patients have higher rates of vascular cancer thrombi, bronchial invasion and positive ALK fusion protein

演題番号 : FP2-19

Speaker)Shaomei Li:1、Cuicui Zhang:1、Qiming Wang:1

1:Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou University, China

Postoperative micropapillary lung adenocarcinoma patients have higher rates of vascular cancer thrombi, bronchial invasion and positive ALK fusion protein

演題取り下げ

演題番号 : FP2-20

演題取り下げ

演題取り下げ

演題番号 : FP2-21

演題取り下げ

Benefits of Etoposide maintenance therapy for patients with extensive SCLC who experienced PR/CR/SD after 4-6 cycles of first-line chemotherapy with etoposide plus cisplatin/carboplatin

演題番号 : FP2-22

Speaker)Zhen He:1、Cuicui Zhang:1、Qiming Wang:1

1:Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou University, China

Benefits of Etoposide maintenance therapy for patients with extensive SCLC who experienced PR/CR/SD after 4-6 cycles of first-line chemotherapy with etoposide plus cisplatin/carboplatin

Successful Return to Intended Oncologic Therapy (RIOT) improving overall survival in lung cancer patients with pathologic stage II and III: Evidence from the real world

演題番号 : FP2-23

Speaker)Wei Dai:1、Qiuling Shi:2、Xuemei Cheng:1、Shaohua Xie:1、Qiang Li:1

1:Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, China、2:Department of Symptom Research, The University of Texas MD Anderson Cancer Center, USA

Successful Return to Intended Oncologic Therapy (RIOT) improving overall survival in lung cancer patients with pathologic stage II and III: Evidence from the real world

演題取り下げ

演題番号 : FP2-24

演題取り下げ

演題取り下げ

演題番号 : FP2-25

演題取り下げ

Lymph node metastases in surgically resected NSCLC with solitary ground-glass opacities

演題番号 : FP2-26

Speaker)Song Xu:1、Shanda Blackmon:2

1:Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, China、2:Thoracic Surgery Division, Mayo Clinic, USA

Lymph node metastases in surgically resected NSCLC with solitary ground-glass opacities

Impact of genetic alterations on outcomes of patients with stage I non-small cell lung cancer: An analysis of the cancer genome atlas data

演題番号 : FP2-27

Speaker)Song Xu:1、Shanda Blackmon:2

1:Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, China、2:Thoracic Surgery Division, Mayo Clinic, USA

Impact of genetic alterations on outcomes of patients with stage I non-small cell lung cancer: An analysis of the cancer genome atlas data

演題取り下げ

演題番号 : FP2-28

演題取り下げ

演題取り下げ

演題番号 : FP2-29

演題取り下げ

Identification and validation of a prognostic signature in malignant pleural mesothelioma

演題番号 : FP2-30

Speaker)Zhou Jian-Guo:1、Ma Hu:1

1:Thoracic Oncology, Department of Oncology, Affiliated Hospital of Zunyi Medical University, China

Identification and validation of a prognostic signature in malignant pleural mesothelioma

Ideal screening model for the primary cervical cancer screening program in country with high prevalence of cervical cancer

演題番号 : FP2-31

Speaker)Taejong Song:1

1:Gynecologic Oncology, Department of Obstetrics & Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea

Ideal screening model for the primary cervical cancer screening program in country with high prevalence of cervical cancer

Current status of treatment of uterine cervical cancer at our department

演題番号 : FP2-32

Speaker)Akiko Abe:1、Masato Nishimura:1、Tomohiro Kagawa:1、Ayuka Mineda:1、Chisato Tonoiso:2、Akiko Kubo:2、Takashi Kawanaka:2、Shunsuke Furutani:2、Hitoshi Ikushima:2、Minoru Irahara:1

1:Obstetrics and Gynecology, Tokushima University Hospital, Japan、2:Radiology, Tokushima University Hospital, Japan

Current status of treatment of uterine cervical cancer at our department

演題取り下げ

演題番号 : FP2-33

演題取り下げ